Contact
searchSearch
HMP Global
Login

Oncology

Featured

Catherine Diefenbach, MD
Videos
Optimizing First-Line Treatment Selection Across in Early- and Advanced-Stage Hodgkin Lymphoma
10/15/2026
Catherine Diefenbach, MD
Catherine Diefenbach, MD, discusses evolving first-lline treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD, discusses evolving first-lline treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD,...
10/15/2026
Oncology
Marc Braunstein, MD, PhD
Videos
CAR T-Cell Therapy Advances Long-Term Disease Control in Relapsed or Refractory Multiple Myeloma
10/15/2026
Marc Braunstein, MD, PhD
Marc Braunstein, MD, PhD, discusses advances in CAR T-cell therapy for patients with relapsed or refractory multiple myeloma, highlighting long-term treatment-free remissions, emerging BCMA-directed therapies such as anitocabtagene...
Marc Braunstein, MD, PhD, discusses advances in CAR T-cell therapy for patients with relapsed or refractory multiple myeloma, highlighting long-term treatment-free remissions, emerging BCMA-directed therapies such as anitocabtagene...
Marc Braunstein, MD, PhD,...
10/15/2026
Oncology
Francesco Maura, MD
Videos
Whole-Genome Sequencing May Distinguish Malignant Transformation From Precursor Multiple Myeloma
10/15/2026
Francesco Maura, MD
Francesco Maura, MD, discusses the evolving role of whole-genome sequencing in multiple myeloma precursor conditions, highlighting how genomic classification may distinguish malignant transformation from non-malignant disease, improve...
Francesco Maura, MD, discusses the evolving role of whole-genome sequencing in multiple myeloma precursor conditions, highlighting how genomic classification may distinguish malignant transformation from non-malignant disease, improve...
Francesco Maura, MD, discusses...
10/15/2026
Oncology
Videos
Round 3: How does route of administration ​and patient preference impact ​treatment selection?​
10/15/2026
Seth Wander MD, PhD; VK Gadi, MD, PhD; Paolo Tarantino, MD, PhD
In the final round, panelists consider how route of administration and patient preference affect treatment selection. They weigh the potential benefits of IV therapy—including more frequent clinical contact, closer toxicity monitoring, and...
In the final round, panelists consider how route of administration and patient preference affect treatment selection. They weigh the potential benefits of IV therapy—including more frequent clinical contact, closer toxicity monitoring, and...
In the final round, panelists...
10/15/2026
Oncology
Videos
Round 2: How should the breadth of pathway inhibition and regimen intensity influence treatment selection after CDK4/6 inhibitor progression?
10/15/2026
Seth Wander MD, PhD; VK Gadi, MD, PhD; Paolo Tarantino, MD, PhD
The discussion turns to how broadly and intensely to inhibit the PI3K/AKT/mTOR pathway after CDK4/6 inhibitor progression. Panelists debate whether broad, multi-node PAM inhibition should be prioritized regardless of PIK3CA status, weighing...
The discussion turns to how broadly and intensely to inhibit the PI3K/AKT/mTOR pathway after CDK4/6 inhibitor progression. Panelists debate whether broad, multi-node PAM inhibition should be prioritized regardless of PIK3CA status, weighing...
The discussion turns to how...
10/15/2026
Oncology
Videos
Round 1: After progression on a CDK4/6 inhibitor, should an actionable mutation determine treatment selection in PIK3CA wild-type disease?
10/15/2026
Seth Wander MD, PhD; VK Gadi, MD, PhD; Paolo Tarantino, MD, PhD
The debate opens with a patient with PIK3CA wild-type disease progressing on an aromatase inhibitor plus a CDK4/6 inhibitor. The panelists debate whether a newly identified actionable mutation should direct the next treatment or instead...
The debate opens with a patient with PIK3CA wild-type disease progressing on an aromatase inhibitor plus a CDK4/6 inhibitor. The panelists debate whether a newly identified actionable mutation should direct the next treatment or instead...
The debate opens with a patient...
10/15/2026
Oncology
Thumbnail
Video Series
Efficacy vs Feasibility: Weighing Timing, Selectivity, and Logistics in PIK3CA Wild-Type HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treatment Sequencing​
10/15/2026
Seth Wander MD, PhD; VK Gadi, MD, PhD; Paolo Tarantino, MD, PhD
Breast cancer experts debate real-world treatment decisions for patients with PIK3CA wild-type HR+/HER2− locally advanced or metastatic breast cancer who have progressed on a CDK4/6 inhibitor.
Breast cancer experts debate real-world treatment decisions for patients with PIK3CA wild-type HR+/HER2− locally advanced or metastatic breast cancer who have progressed on a CDK4/6 inhibitor.
Breast cancer experts debate...
10/15/2026
Oncology
Olatunji Alese, MD, and Efrat Dotan, MD
Videos
Balancing Promise and Uncertainty With RAS Inhibitors in Pancreatic Cancer
10/14/2026
Olatunji Alese, MD; Efrat Dotan, MD
Olatunji Alese, MD, and Efrat Dotan, MD, discuss the emerging role of RAS inhibitors in pancreatic cancer, weighing significant efficacy advances against questions surrounding real-world patient selection, resistance, long-term outcomes,...
Olatunji Alese, MD, and Efrat Dotan, MD, discuss the emerging role of RAS inhibitors in pancreatic cancer, weighing significant efficacy advances against questions surrounding real-world patient selection, resistance, long-term outcomes,...
Olatunji Alese, MD, and Efrat...
10/14/2026
Oncology
FDA Approval
FDA Expands Nogapendekin Alfa Inbakicept Plus Bacillus Calmette-Guérin Approval to Include High-Grade Papillary-Only Bladder Cancer
10/14/2026
Emily Estrada
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication...
10/14/2026
Oncology
Stephanie Berg, DO
Videos
Doublet Therapy Remains Central to First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma
10/14/2026
Stephanie Berg, DO
Stephanie Berg, DO, discusses first-line treatment selection for patients with metastatic clear cell renal cell carcinoma, highlighting the trade-offs between dual immunotherapy and immunotherapy plus tyrosine kinase inhibitor combinations,...
Stephanie Berg, DO, discusses first-line treatment selection for patients with metastatic clear cell renal cell carcinoma, highlighting the trade-offs between dual immunotherapy and immunotherapy plus tyrosine kinase inhibitor combinations,...
Stephanie Berg, DO, discusses...
10/14/2026
Oncology
Gail Roboz, MD
Videos
All-Oral Treatment Strategy May Reduce Treatment Burden in Acute Myeloid Leukemia
10/14/2026
Gail Roboz, MD
Gail Roboz, MD, discusses results from the phase 1/2 ASCERTAIN-V trial evaluating all-oral decitabine and cedazuridine plus venetoclax in patients with acute myeloid leukemia ineligible for intensive chemotherapy, highlighting encouraging...
Gail Roboz, MD, discusses results from the phase 1/2 ASCERTAIN-V trial evaluating all-oral decitabine and cedazuridine plus venetoclax in patients with acute myeloid leukemia ineligible for intensive chemotherapy, highlighting encouraging...
Gail Roboz, MD, discusses...
10/14/2026
Oncology

Videos

Catherine Diefenbach, MD
Videos
Optimizing First-Line Treatment Selection Across in Early- and Advanced-Stage Hodgkin Lymphoma
10/15/2026
Catherine Diefenbach, MD
Catherine Diefenbach, MD, discusses evolving first-lline treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD, discusses evolving first-lline treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...
Catherine Diefenbach, MD,...
10/15/2026
Oncology
Marc Braunstein, MD, PhD
Videos
CAR T-Cell Therapy Advances Long-Term Disease Control in Relapsed or Refractory Multiple Myeloma
10/15/2026
Marc Braunstein, MD, PhD
Marc Braunstein, MD, PhD, discusses advances in CAR T-cell therapy for patients with relapsed or refractory multiple myeloma, highlighting long-term treatment-free remissions, emerging BCMA-directed therapies such as anitocabtagene...
Marc Braunstein, MD, PhD, discusses advances in CAR T-cell therapy for patients with relapsed or refractory multiple myeloma, highlighting long-term treatment-free remissions, emerging BCMA-directed therapies such as anitocabtagene...
Marc Braunstein, MD, PhD,...
10/15/2026
Oncology
Francesco Maura, MD
Videos
Whole-Genome Sequencing May Distinguish Malignant Transformation From Precursor Multiple Myeloma
10/15/2026
Francesco Maura, MD
Francesco Maura, MD, discusses the evolving role of whole-genome sequencing in multiple myeloma precursor conditions, highlighting how genomic classification may distinguish malignant transformation from non-malignant disease, improve...
Francesco Maura, MD, discusses the evolving role of whole-genome sequencing in multiple myeloma precursor conditions, highlighting how genomic classification may distinguish malignant transformation from non-malignant disease, improve...
Francesco Maura, MD, discusses...
10/15/2026
Oncology
Videos
Round 3: How does route of administration ​and patient preference impact ​treatment selection?​
10/15/2026
Seth Wander MD, PhD; VK Gadi, MD, PhD; Paolo Tarantino, MD, PhD
In the final round, panelists consider how route of administration and patient preference affect treatment selection. They weigh the potential benefits of IV therapy—including more frequent clinical contact, closer toxicity monitoring, and...
In the final round, panelists consider how route of administration and patient preference affect treatment selection. They weigh the potential benefits of IV therapy—including more frequent clinical contact, closer toxicity monitoring, and...
In the final round, panelists...
10/15/2026
Oncology
Videos
Round 2: How should the breadth of pathway inhibition and regimen intensity influence treatment selection after CDK4/6 inhibitor progression?
10/15/2026
Seth Wander MD, PhD; VK Gadi, MD, PhD; Paolo Tarantino, MD, PhD
The discussion turns to how broadly and intensely to inhibit the PI3K/AKT/mTOR pathway after CDK4/6 inhibitor progression. Panelists debate whether broad, multi-node PAM inhibition should be prioritized regardless of PIK3CA status, weighing...
The discussion turns to how broadly and intensely to inhibit the PI3K/AKT/mTOR pathway after CDK4/6 inhibitor progression. Panelists debate whether broad, multi-node PAM inhibition should be prioritized regardless of PIK3CA status, weighing...
The discussion turns to how...
10/15/2026
Oncology
Videos
Round 1: After progression on a CDK4/6 inhibitor, should an actionable mutation determine treatment selection in PIK3CA wild-type disease?
10/15/2026
Seth Wander MD, PhD; VK Gadi, MD, PhD; Paolo Tarantino, MD, PhD
The debate opens with a patient with PIK3CA wild-type disease progressing on an aromatase inhibitor plus a CDK4/6 inhibitor. The panelists debate whether a newly identified actionable mutation should direct the next treatment or instead...
The debate opens with a patient with PIK3CA wild-type disease progressing on an aromatase inhibitor plus a CDK4/6 inhibitor. The panelists debate whether a newly identified actionable mutation should direct the next treatment or instead...
The debate opens with a patient...
10/15/2026
Oncology
Olatunji Alese, MD, and Efrat Dotan, MD
Videos
Balancing Promise and Uncertainty With RAS Inhibitors in Pancreatic Cancer
10/14/2026
Olatunji Alese, MD; Efrat Dotan, MD
Olatunji Alese, MD, and Efrat Dotan, MD, discuss the emerging role of RAS inhibitors in pancreatic cancer, weighing significant efficacy advances against questions surrounding real-world patient selection, resistance, long-term outcomes,...
Olatunji Alese, MD, and Efrat Dotan, MD, discuss the emerging role of RAS inhibitors in pancreatic cancer, weighing significant efficacy advances against questions surrounding real-world patient selection, resistance, long-term outcomes,...
Olatunji Alese, MD, and Efrat...
10/14/2026
Oncology
Stephanie Berg, DO
Videos
Doublet Therapy Remains Central to First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma
10/14/2026
Stephanie Berg, DO
Stephanie Berg, DO, discusses first-line treatment selection for patients with metastatic clear cell renal cell carcinoma, highlighting the trade-offs between dual immunotherapy and immunotherapy plus tyrosine kinase inhibitor combinations,...
Stephanie Berg, DO, discusses first-line treatment selection for patients with metastatic clear cell renal cell carcinoma, highlighting the trade-offs between dual immunotherapy and immunotherapy plus tyrosine kinase inhibitor combinations,...
Stephanie Berg, DO, discusses...
10/14/2026
Oncology
Gail Roboz, MD
Videos
All-Oral Treatment Strategy May Reduce Treatment Burden in Acute Myeloid Leukemia
10/14/2026
Gail Roboz, MD
Gail Roboz, MD, discusses results from the phase 1/2 ASCERTAIN-V trial evaluating all-oral decitabine and cedazuridine plus venetoclax in patients with acute myeloid leukemia ineligible for intensive chemotherapy, highlighting encouraging...
Gail Roboz, MD, discusses results from the phase 1/2 ASCERTAIN-V trial evaluating all-oral decitabine and cedazuridine plus venetoclax in patients with acute myeloid leukemia ineligible for intensive chemotherapy, highlighting encouraging...
Gail Roboz, MD, discusses...
10/14/2026
Oncology
Ashley Plant-Fox, MD, Lurie Children's Hospital
Videos
Treating Progressive Optic Pathway Glioma With Tovorafenib
10/13/2026
Ashley Plant-Fox, MD, discusses a case of progressive BRAF fusion–positive optic pathway glioma and how treatment with tovorafenib reduced tumor size, resolved headaches, and ended the need for further shunt revisions.
Ashley Plant-Fox, MD, discusses a case of progressive BRAF fusion–positive optic pathway glioma and how treatment with tovorafenib reduced tumor size, resolved headaches, and ended the need for further shunt revisions.
Ashley Plant-Fox, MD, discusses...
10/13/2026
Oncology

Insights From the ASCO Annual Meeting

News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
Adjuvant Erlotinib Following Complete Resection of EGFR-Mutant Non-Small Cell Lung Cancer Improves Disease Free Survival But Not Overall Survival
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
Concurrent Radiotherapy, Chemotherapy, and Durvalumab Does Not Improve Outcomes in Extensive-Stage Small Cell Lung Cancer
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
Health-Related Quality of Life Preserved with Neoadjuvant and Adjuvant Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
Pralsetinib Shows Improved Response in RET Fusion–Positive Advanced or Metastatic Non–Small Cell Lung Cancer
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
Vorasidenib Maintains Durable Clinical Benefit With Consistent Safety in IDH-Mutated Glioma
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

FDA Approval
FDA Expands Nogapendekin Alfa Inbakicept Plus Bacillus Calmette-Guérin Approval to Include High-Grade Papillary-Only Bladder Cancer
10/14/2026
Emily Estrada
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication...
10/14/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Advanced Desmoid Tumors
10/09/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial...
10/09/2026
Oncology
News
Iberdomide Plus Daratumumab and Dexamethasone Significantly Improves PFS in Relapsed or Refractory Multiple Myeloma
10/08/2026
Stephanie Holland
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3...
10/08/2026
Oncology
News
Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology
News
Acute Myeloid Leukemia Transformation Emerges as Strongest Predictor of Relapse After Allogenic-HSCT in Myelodysplastic Syndromes
10/08/2026
Emily Estrada
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of...
10/08/2026
Oncology
News
Epcoritamab Plus R-CHOP Improves Progression-Free Survival Over R-CHOP Alone in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma
10/08/2026
Emily Estrada
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3...
10/08/2026
Oncology
News
SurVaxM Shows Survival Signal in Newly Diagnosed Glioblastoma, With Significant Benefit in Younger Patients
10/07/2026
Emily Estrada
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b...
10/07/2026
Oncology
FDA Approval
FDA Approves Tucatinib Plus Trastuzumab and Pertuzumab for Maintenance Treatment of HER2-Positive Advanced Breast Cancer
10/07/2026
Stephanie Holland
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the...
10/07/2026
Oncology
FDA Approval
FDA Expands Pirtobrutinib to First-Line Treatment of CLL/SLL Without 17p Deletion
10/02/2026
Stephanie Holland
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN...
10/02/2026
Oncology
News
Risvutatug Rezetecan More Than Doubles Response and Significantly Extends Survival in Patients With Relapsed Small Cell Lung Cancer
09/29/2026
Emily Estrada
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3...
09/29/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use